Physician profile
Tamara R Fountain
NPI 1033110978
$1,046,193.33
in general payments reported to CMS, 2019-2025
12 companies · $278K in 2025
The $278K reported for 2025 was more than what 99% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,428 · 2020: $136 · 2021: $162 · 2022: $27.19 · 2023: $566K · 2024: $199K · 2025: $278K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $819K · Consulting Fee: $218K · Education: $2,900 · Travel and Lodging: $1,979 · Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $819,257.45 |
| Consulting Fee | $218,430.00 |
| Education | $2,900.00 |
| Travel and Lodging | $1,978.80 |
| Food and Beverage | $873.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $993,629.48 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $47,818.70 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $2,244.99 | 2019-2021 | |
| Oyster Point Pharma, INC. | $1,930.00 | 2024 | |
| Alcon Vision LLC | $143.29 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $113.85 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $85.87 | 2019 | |
| Bausch & Lomb Americas INC. | $44.60 | 2023 | Lotemax Sm |
| Biotissue Holdings INC. | $23.67 | 2021 | |
| New World Medical,INC. | $17.40 | 2023 | |
| Sun Pharmaceutical Industries INC. | $16.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$626,822.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Fountain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.